Value sales of analgesics continue to rise in Australia in 2022 following a particularly strong performance the previous year when demand was partly driven by the ongoing effects of the pandemic and stockpiling tendencies. Whilst habit persistence is maintaining overall demand for popular analgesics such as acetaminophen and ibuprofen, the easing of restrictions in Australia, in line with the country’s rollout of its vaccination campaign and a fall in COVID-19 cases, has led to greater mobility...

Euromonitor International’s Analgesics in Australia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.


Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years’ experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.